Award type :
Product Development Award
Product Development Award
Product type :
Vaccines
Vaccines
Award year :
2020
2020
Project start date :
08 / 14 / 2020
08 / 14 / 2020
Project end date :
06 / 30 / 2021
06 / 30 / 2021
Project duration (months) :
12
12
Development stage :
Preclinical
Preclinical
Target disease :
Influenza, Respiratory
Influenza, Respiratory
Region served :
World
World
Recipient organization / Country of funding recipient organization :
Genexine / Republic of Korea
Genexine / Republic of Korea
Collaborator(s) / Country :
-
-
Funding amount(KRW) :
500,000,000
500,000,000
This project by Genexine is a safety study of engineered long-acting IL-7 that enhances the T-cell immune response and provides protection in an influenza lethality model. This vaccine reflects a pathogen agnostic approach and can be used in future outbreaks of viral respiratory infections.